Ipamorelin is a selective growth hormone secretagogue (GHS) that stimulates the pituitary gland to release growth hormone (GH). It is often studied for its ability to produce a more physiological release of GH with minimal impact on other hormones.
Ipamorelin acts as a ghrelin mimetic, binding to the ghrelin receptor in the pituitary gland. This binding selectively stimulates the release of GH, promoting natural GH pulsatility. Unlike some other GHS, Ipamorelin is noted for its selectivity, generally avoiding the significant release of cortisol, prolactin, or ACTH.
Clinical and preclinical research has explored Ipamorelin in the context of:
Its selective action makes it a subject of interest for researchers looking to modulate GH levels with fewer side effects.
Ipamorelin’s regulatory status may vary depending on jurisdiction and current policy. In many regions, it is considered a research chemical and is not approved for human therapeutic use. Researchers should consult the latest guidelines from regulatory bodies like the FDA in the US or EMA in Europe for specific guidance. For a general overview, refer to our U.S. peptide legal status tracker.
Researchers comparing Ipamorelin products often evaluate:
PeptideChecker tracks Ipamorelin product listings across multiple suppliers to help researchers compare availability, pricing, and quality.
Q: What is Ipamorelin primarily used for in research? A: Ipamorelin is primarily studied for its selective stimulation of growth hormone release.
Q: How is Ipamorelin typically administered in research settings? A: Common administration routes in research include subcutaneous injection.
Q: Where can I find verified suppliers for Ipamorelin? A: Our supplier comparison tool provides a list of vendors offering Ipamorelin with purity and pricing details.
\n\n